生长抑素受体闪烁扫描术在小细胞肺癌分期中的应用
Somatostatin receptor scintigraphy in the staging of small cell lung cancer.
作者信息
Bohuslavizki K H, Brenner W, Günther M, Eberhardt J U, Jahn N, Tinnemeyer S, Wolf H, Sippel C, Clausen M, Gatzemeier U, Henze E
机构信息
Clinic of Nuclear Medicine, Christian-Albrechts-Universität Kiel, Germany.
出版信息
Nucl Med Commun. 1996 Mar;17(3):191-6. doi: 10.1097/00006231-199603000-00003.
The aim of this study was to evaluate somatostatin receptor scintigraphy (SRS) in the staging of patients with small cell lung cancer. Prior to chemotherapy, 20 patients were investigated up to 24 h following an injection of 200 MBq 111In-octreotide. Following chemotherapy and restaging, four patients were re-evaluated. Primary tumour was detected in 18 of 23 studies, which exhibited increasing target-to-back-ground ratios over time. Lymph node metastases and distant metastases were detected in 7 of 27 and 8 of 31 sites, respectively. Thus, the overall sensitivity for detecting metastases was less than 26%. SRS did not result in any upstaging of patients. We conclude that in patients with small cell lung cancer, functional imaging by SRS has no impact on clinical decision making.
本研究的目的是评估生长抑素受体闪烁显像（SRS）在小细胞肺癌患者分期中的作用。化疗前，对20例患者注射200MBq的111In-奥曲肽后进行长达24小时的检查。化疗及重新分期后，对4例患者进行了重新评估。23项研究中有18项检测到了原发性肿瘤，其靶本底比值随时间增加。在27个部位中的7个部位和31个部位中的8个部位分别检测到了淋巴结转移和远处转移。因此，检测转移灶的总体敏感性低于26%。SRS并未导致任何患者分期上调。我们得出结论，在小细胞肺癌患者中，SRS功能成像对临床决策没有影响。
Zotero 插件